Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.

BACKGROUND: In patients with multiply relapsed Hodgkin's lymphoma allogeneic stem-cell transplantation has been limited by prohibitive non-relapse-related mortality rates and by a lack of definitive evidence for a therapeutic graft-versus-tumour effect. Therefore, we aimed to assess the graft-...

Bibliográfalaš dieđut
Váldodahkkit:	Peggs, K, Hunter, A, Chopra, R, Parker, A, Mahendra, P, Milligan, D, Craddock, C, Pettengell, R, Dogan, A, Thomson, K, Morris, E, Hale, G, Waldmann, H, Goldstone, A, Linch, D, Mackinnon, S
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2005

Geahča maid

Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation.
Dahkki: Mackinnon, S, et al.
Almmustuhtton: (1999)

Excessive T-cell depletion adversely affects transplant-related mortality following allogeneic stem cell transplantation.
Dahkki: Chakraverty, R, et al.
Almmustuhtton: (2000)

Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation.
Dahkki: Chakraverty, R, et al.
Almmustuhtton: (2001)

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Dahkki: Chakraverty, R, et al.
Almmustuhtton: (2002)

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Dahkki: Kottaridis, P, et al.
Almmustuhtton: (2000)

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2002)

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Dahkki: Kottaridis, P, et al.
Almmustuhtton: (2001)

A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy.
Dahkki: Kottaridis, P, et al.
Almmustuhtton: (1999)

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
Dahkki: Mead, A, et al.
Almmustuhtton: (2010)

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Dahkki: Peggs, K, et al.
Almmustuhtton: (2003)

Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?
Dahkki: Karl S. Peggs
Almmustuhtton: (2018-04-01)

T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions.
Dahkki: D'Sa, S, et al.
Almmustuhtton: (2003)

Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab.
Dahkki: Avivi, I, et al.
Almmustuhtton: (2004)

Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2002)

An unusual case of intrapulmonary granulocytic sarcoma presenting as interstitial pneumonitis following allogeneic bone marrow transplantation for acute myeloid leukaemia and responding to donor lymphocyte infusion.
Dahkki: Kottaridis, P, et al.
Almmustuhtton: (1999)

Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation.
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2003)

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
Dahkki: Chakraverty, R, et al.
Almmustuhtton: (2010)

Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study
Dahkki: Emma Das-Gupta, et al.
Almmustuhtton: (2019-12-01)

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Dahkki: Ferguson, P, et al.
Almmustuhtton: (2016)

Results of allogeneic hematopoietic stem cell transplantation in a patient with classical Hodgkin's lymphoma
Dahkki: A. Р. Strelnikova, et al.
Almmustuhtton: (2021-05-01)

Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients
Dahkki: Swati Naik, et al.
Almmustuhtton: (2019-09-01)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
Dahkki: Schwenkglenks Matthias, et al.
Almmustuhtton: (2010-08-01)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.
Dahkki: Craddock, C, et al.
Almmustuhtton: (2010)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
Dahkki: Ahmet Dogan
Almmustuhtton: (2022-10-01)

Use of Ceprate CD34-positive selection system for depletion of T cells in allogeneic transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1997)

Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation
Dahkki: Michael A. Spinner, et al.
Almmustuhtton: (2018-07-01)

Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma
Dahkki: Nadeem Tabbara, et al.
Almmustuhtton: (2025-03-01)

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
Dahkki: Evgeny Klyuchnikov, et al.
Almmustuhtton: (2011-01-01)

Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma
Dahkki: Shiliang Ge, et al.
Almmustuhtton: (2025-02-01)

PB2435: ALLOGENEIC STEM CELL TRANSPLANTATION OUTCOMES IN HODGKIN LYMPHOMA: A PROGNOSTIC STUDY OF 30 PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
Dahkki: Shayan Zamani, et al.
Almmustuhtton: (2023-08-01)

CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
Dahkki: Luca Castagna, et al.
Almmustuhtton: (2015-02-01)

Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation
Dahkki: Manar S. Shafat, et al.
Almmustuhtton: (2020-07-01)

LYMPHOID NEOPLASMS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION. THE CASE OF SECONDARY HODGKIN’S LYMPHOMA, DIFFERENTIAL DIAGNOSIS WITH POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE
Dahkki: Yu. V. Skvortsova, et al.
Almmustuhtton: (2017-06-01)

Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis
Dahkki: Nirav N. Shah, et al.
Almmustuhtton: (2021-04-01)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2004)

Localised crystal‐storing histiocytosis in a classical Hodgkin lymphoma patient post allogeneic transplant
Dahkki: Carol Kwon, et al.
Almmustuhtton: (2023-11-01)

T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2003)

LONG-TERM OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY HODGKIN AND NON-HODGKIN LYMPHOMA: MULTI-CENTER EXPERINCE FROM TURKEY
Dahkki: Ayse Uysal, et al.
Almmustuhtton: (2023-10-01)